Serum Institute of India gets CDSCO Panel nod to study Dengue Monoclonal Antibody

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2024-10-03 12:30 GMT | Update On 2024-10-03 12:30 GMT

New Delhi: Serum Institute of India has got a go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to conduct the Phase III clinical trial of dengue monoclonal antibody in children ≥ 5 years and adults with dengue.

This came after Serum Institute of India presented the proposal to conduct a Phase III clinical trial titled “A Phase III, double-blind, randomized, placebo-controlled, multicentric study of dengue monoclonal antibody in children ≥ 5 years and adults with dengue” via protocol number: Dengue-mAb-03version 1.0, dated 04 Jul 2024 along with the results of the Phase II study.

The Serum Institute of India (SII) is developing a dengue monoclonal antibody drug called Dengushield, which is an antiviral and orphan drug.

Dengue monoclonal antibody is an engineered humanised monoclonal antibody that binds to a non-immunodominant epitope on domain III of the envelope protein (EDIII) and has shown potent, specific neutralisation of all four serotypes of dengue virus.

At the recent SEC meeting for Antimicrobial and Antiviral held on 19th September 2024, the expert panel reviewed the proposal presented by the drug major Serum Institute to conduct the Phase III clinical trial of the antimicrobial drug Dengue Monoclonal Antibody (Recombinant Dengue mAb).

The committee reviewed the results of the Phase II study.

After detailed deliberation, the committee recommended a grant of permission to conduct the Phase III clinical trial as per the protocol presented by the firm.

Also Read: CDSCO Panel Approves IQVIA RDS Protocol Amendment Proposal for Survodutide study

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Dr. Divya Colin

Dr. Divya Colin, a Doctor of Pharmacy Graduate with extensive experience in clinical and hospital settings and confidently equipped with diagnostic and therapeutic skills. She also has spread out exposure to Oncology Departments in Mysore Medical College and Research Institute as Oncology Pharmacist. Currently she is building a career in clinical research and clinical data management. She has been a part of Medical Dialogue since January 2022.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Serum Institute of India gets CDSCO Panel nod to study Dengue Monoclonal Antibody

Similar News

Delhi HC Refuses to Lift Ban on Medipol Pharma After Substandard Clarithromycin, Noscapine Supplied to Armed Forces

Biocon Opens First US Manufacturing Facility in New Jersey, Invests USD 30 Million in Expansion

USFDA Reappoints Vinay Prasad to Top Medical and Scientific Role

B Pharmacy Graduate Held for Operating Unauthorized Clinic in Hyderabad

No Generics for AbbVie's Rinvoq Until 2037, Analysts See Multi-Billion Dollar Boost

Advent to Sell Zentiva to Private Equity GTCR in USD 4.8 Billion Deal, Closing Expected in 2026

Chennai Court Acquits 2 After Alleged Nitravet Haul Found to Be Paracetamol

USFDA warns pharma cos to remove misleading ads